CJC-1295 + Ipamorelin

A research protocol combining two complementary growth hormone-stimulating peptides: CJC-1295 (a GHRH analogue acting on GHRH receptors) and Ipamorelin (a GHRP acting on the ghrelin/GHS-R1a receptor). The two classes work through distinct pituitary pathways that amplify each other — GHRH analogues increase GH pulse amplitude while GHRPs increase both amplitude and frequency. Preclinical research suggests synergistic GH and IGF-1 elevation greater than either compound alone.